Kiran N null, Jammula Pavani, Kurra Rahul, Meghana Patel, A. Anitha null
This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.
Introduction: Atrial fibrillation can be disturbing to the patient, may present as palpitations, syncope. When persistent and causing Haemodynamic disturbances to be treated, either pharmacologically when stable or with Cardioversion under sedation.
Case Report: Our patient aged 50 years male presented with pain abdomen, diagnosed as cholelithiasis. He also presented with palpitations, with an irregular heart rate, giddiness; when ECG was taken it showed a Heart rate of 130 to 150 and had no p waves and irregularly irregular. (Figure 1) (to add).
ECG Showed Atrial Fibrillation and Left Ventricular hypertrophy, Chest X-ray showed increased bronchovascular markings; 2D ECHO showed Mild Concentric LVH, Trivial MR and AR, Mild TR; EF:50%,HbA1c of 9.3%. Other Investigations within normal limits.
Patient was started on Tab. Metoprolol 50mg Twice daily and Tab Rivaxa 20mg once daily for one week and heart rate came down to 70bpm.Tab Rivaxa was stopped 12 hrs before surgery.
Premedicated with Inj.Fentanyl 100mcg, Inj.Loxicard 100mg, Induced with Inj. Propofol 100mg and Intubated with Inj Suxamethonium 100mg. Maintained with O2, N2O and Isoflurane and Inj Vecuronium. Monitored with HR, NIBP, SPO2, Temperature. IV fluids RL&NS were given. Analgesia with Fentanyl, IV Paracetamol. Was uneventful. Reversed with Inj Neostigmine & Inj Glycopyrrolate and extubated. Post-operative period was uneventful.
Conclusion: We successfully managed a patient with symptomatic Atrial Fibrillation with B blockers and without cardioversion.
Subramaniam S, Haribabu V. Comparison between levobupivacaine vs ropivacaine in thoracic epidural anaesthesia for modified radical mastectomy: a randomised controlled trial. Ind J Anesth Analg. 2025;12(4):295-6.
This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.
| Received | Accepted | Published |
|---|---|---|
| October 04, 2025 | December 13, 2025 | December 30, 2025 |
Saturday 07 February 2026, 19:14:05 (IST)
Download citation
Highlight selected keywords in the article text.
| Received | October 04, 2025 |
| Accepted | December 13, 2025 |
| Published | December 30, 2025 |
This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.